Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

151
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
151
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

594
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
594
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

237
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
237

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cortical gray-white matter contrast alterations precede amyloid-β positivity and macrostructural changes in older adults without dementia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Mediation Analysis Between Brain Age, Disease-Modifying Factors, and Disability and Cognitive Performance in Multiple Sclerosis.

Neurology·2026
Same author

Message From the Editors to Our Reviewers.

Neurology·2026
Same author

Decreased amyloid-related structure-function coupling in preclinical Alzheimer's disease.

Communications medicine·2026
Same author

The constrained brain in multiple sclerosis: Cognitive impairment is related to network-specific coupling of structural and functional connectivity.

Multiple sclerosis journal - experimental, translational and clinical·2026
Same author

Longitudinal Change in Blood-Based Biomarkers and the Association With MRI-Measured Neurodegeneration in Cognitively Unimpaired Individuals.

Neurology·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Aug 11, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.6K

Interpretable machine learning for dementia: A systematic review.

Sophie A Martin1,2, Florence J Townend1, Frederik Barkhof1,2,3

  • 1Centre for Medical Image Computing, Department of Computer Science, University College London, London, UK.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|February 3, 2023
PubMed
Summary
This summary is machine-generated.

Interpretable machine learning shows promise for automated dementia diagnosis, but robust validation and clinical integration are needed. Future research must focus on clinician involvement and patient-specific explanations for real-world impact.

Keywords:
dementiadiagnosisexplainable artificial intelligenceinterpretabilitymachine learningmild cognitive impairment

More Related Videos

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.2K
Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

21.7K

Related Experiment Videos

Last Updated: Aug 11, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.6K
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.2K
Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

21.7K

Area of Science:

  • Artificial Intelligence in Medicine
  • Computational Neuroscience

Background:

  • Automated dementia diagnosis using machine learning (ML) is growing but lacks clinical utility.
  • Key challenges include developing robust, generalizable, and explainable ML models.
  • Interpretable models and post hoc explainability methods are crucial for clinical trust.

Approach:

  • A systematic literature review identified 92 studies on interpretable ML for dementia diagnosis.
  • Analysis focused on classification performance, validation, and reporting standards.
  • Evaluation of current state-of-the-art in explainable AI for neurodegenerative diseases.

Key Points:

  • Studies show promising classification performance but exhibit variability in validation and reporting.
  • Over-reliance on popular datasets limits generalizability.
  • Understanding interpretability methods is critical for analyzing model explanations.

Conclusions:

  • Future work requires clinician collaboration for validating explanation methods and inferring disease pathology.
  • Patient-specific explanations are essential to demonstrate clinical benefits.
  • Enhanced validation and reporting standards are needed for reliable AI in dementia care.